Skip to content

Study · Randomized controlled trial · n = 398 · 2016

9 results

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.

Rodbard HW, Buse JB, Woo V, Vilsbøll T, Langbakke IH, Kvist K, Gough SC

Diabetes, obesity & metabolism5 Nov 2015Cited by 27 (Europe PMC)

PMID26343931 (opens in a new tab)PMCIDPMC5063148 (opens in a new tab)DOI10.1111/dom.12574 (opens in a new tab)PepBankPUB-26343931
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin plus OADs, IDegLira reduced HbA1c significantly more than IDeg in all but the lowest baseline HbA1c category.

    In plain wordsIn people with type 2 diabetes on basal insulin, the combination with liraglutide lowered HbA1c more than insulin alone, except at the lowest starting HbA1c.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction by baseline HbA1c category, DUAL II
    Study

    n = 398

    Comparator
    IDeg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    0.9 to 2.5%
    IDegLira, DUAL II

    Source sentences

    Summary
    In DUAL II, HbA1c reductions were significantly greater with IDegLira (0.9-2.5%) than with IDeg in all but the lowest HbA1c category.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, insulin dose was similar with IDegLira and IDeg, independent of baseline HbA1c.

    In plain wordsIn people with type 2 diabetes on basal insulin, the insulin dose was similar with the combination product and with insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin dose, DUAL II
    Study

    n = 398

    Comparator
    IDeg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In DUAL II, insulin dose and hypoglycaemia rate were similar with IDegLira and IDeg (maximum dose limited to 50 U) independent of baseline HbA1c.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, the hypoglycaemia rate was similar with IDegLira and IDeg, independent of baseline HbA1c.

    In plain wordsIn type 2 diabetes on basal insulin, low blood sugar happened at a similar rate with the combination product and insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia rate, DUAL II
    Study

    n = 398

    Comparator
    IDeg
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In DUAL II, insulin dose and hypoglycaemia rate were similar with IDegLira and IDeg (maximum dose limited to 50 U) independent of baseline HbA1c.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)
  4. 04HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, insulin dose was lower with IDegLira than with IDeg across all baseline HbA1c categories.

    In plain wordsIn people with type 2 diabetes, the combination product with liraglutide needed a lower insulin dose than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin dose, DUAL I
    Study

    n: not reported in source

    Comparator
    IDeg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)
  5. 05HumanRandomized controlled trialSafety outcome

    In insulin-naive adults with type 2 diabetes, the hypoglycaemia rate was lower with IDegLira than with IDeg across all baseline HbA1c categories.

    In plain wordsIn people with type 2 diabetes, low blood sugar happened less often with the combination product with liraglutide than with insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia rate versus IDeg, DUAL I
    Study

    n: not reported in source

    Comparator
    IDeg
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes uncontrolled on OADs, IDegLira reduced HbA1c significantly more than IDeg or liraglutide alone across baseline HbA1c categories.

    In plain wordsIn people with type 2 diabetes, the insulin degludec plus liraglutide product lowered HbA1c more than either component alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction by baseline HbA1c category, DUAL I
    Study

    n: not reported in source

    Comparator
    IDeg or liraglutide alone (pooled)
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c reduction
    1.1 to 2.5%
    IDegLira, DUAL I

    Source sentences

    Summary
    Across four categories of baseline HbA1c (≤7.5-9.0%), HbA1c reductions were significantly greater with IDegLira (1.1-2.5%) compared with IDeg or liraglutide alone in DUAL I.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 07HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In insulin-naive adults with type 2 diabetes, hypoglycaemia was higher with IDegLira than with liraglutide alone, irrespective of baseline HbA1c.

    In plain wordsIn people with type 2 diabetes, low blood sugar was more common with the insulin plus liraglutide product than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseHypoglycaemia versus liraglutide alone, DUAL I
    Study

    n: not reported in source

    Comparator
    Liraglutide alone
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    while hypoglycaemia was higher with IDegLira than liraglutide, irrespective of baseline HbA1c.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the HbA1c reduction with IDegLira was independent of disease duration and previous insulin dose.

    In plain wordsIn type 2 diabetes, the HbA1c fall with the insulin plus liraglutide product did not depend on diabetes duration or past insulin dose.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c reduction by disease duration and previous insulin dose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The reduction in HbA1c with IDegLira was independent of disease duration and previous insulin dose
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the HbA1c reduction with IDegLira varied depending on pre-trial OAD treatment.

    In plain wordsIn people with type 2 diabetes, the HbA1c fall with the insulin plus liraglutide product differed by the tablets taken before the trial.

    Peptide
    Liraglutide
    Outcome
    MixedHbA1c reduction by pre-trial OAD treatment
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    but varied depending on pre-trial OAD treatment.
    1 context sentence
    Summary · context
    Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks)

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.